CTEXDEV develops Augmentative and Alternative Communication (AAC) applications called CommunicoTool, to help non-verbal individuals to communicate.Industry sectors E_health
Our innovative solution
CommunicoTool is an Augmentative and Alternative Communication (AAC) application that provide language communication features including: pictures and pictograms, prerecorded voice, speech synthesis, speech/pain assessment, time management. The application is fully configurable by the end users. Our service is available in French and English in a bilingual version.Problem solved
CommunicoTool is an application for tablets suitable for patients with ASD, Stroke, LAS, Cerebral pulsy, with language and communication disorders. Just for ASD, The CDC (Centers for Disease Control and Prevention) estimates about 1 percent of the world population (7 billion) has autism spectrum disorder, and more than 25% of them are non-verbal.
ASD / Stroke / LAS / Cerebral pulsy
Accessibility / price / Innovation / Configurable
Frederic GuibetCEO - Founder
Nutrition and Weight Loss
Your innovative solution
The costs of healthcare become more and more disabling for the modern-day families. Because of these costs, they tend to avoid taking medical appointments. Our objective is to allow every individual to be the master of his own health capital.
Firms, Works Council, Mutual insurance companies, Insurances?
Prepaid voucher, Online appointment setting, Intelligent health record, Directory of the healthcare professionals
Center for Human Reproduction
Welcome to the Center for Human Reproduction (CHR), a leading fertility center located in New York City. CHR is known as a “fertility center of last resort,” primarily serving patients who have previously failed treatments elsewhere. Among CHR’s areas of special expertise are treatments of “older” ovaries, whether due to advanced female age or premature ovarian aging (POA), immunological problems affecting reproduction, repeated pregnancy loss, endometriosis, polycystic ovary syndrome (PCOS), tubal disease, male factor infertility, etc.
Dr Norbert GleicherMedical Director
Harnessing the brain’s immune system to fight neurodegeneration.
CereSpir is leading the way with a completely novel approach to Alzheimer’s disease (AD) by reducing inflammation and increasing clearance of tissue debris in the brain as a potential first disease-modifying treatment targeting the very earliest stages of the disease.
CSP-1103, an orally delivered tablet, has undergone Phase 2 testing in people with Mild Cognitive Impairment (MCI). The Company aims to initiate Phase 3 trials in 2015. CSP-1103 is a novel, first-in-class, small molecule microglial modulator that protects neurons and other cells in the brain. CSP-1103 is a novel, first-in-class, small molecule microglial modulator that protects neurons and other cells in the brain.
Professor Daniel ChainPresident & Chief Executive Officer
Chromocell is a life sciences company which improves consumer products and patient lives through breakthrough science and technologies. Chromocell is focused on the discovery and development of therapeutics and flavors through the use of pioneering Chromovert® technology. Chromovert technology enables Chromocell to use rare cells ideally suited for effective high-throughput screening. Chromocell’s therapeutics pipeline is currently focused on analgesics and rare diseases, where Chromovert technology has proven highly effective in the rapid identification of potential new drug candidates. In our flavors and nutrition business, Chromocell works with global consumer goods companies to discover and develop flavor ingredients and natural taste enhancers. The technology is applicable to all areas of taste sensations as well as aroma and fragrance enhancer discovery.
Dr Tina GaryantesVice President, Therapeutics
The Private Company Access team leverages Citigroup’s strength and expertise in Institutional Sales and Trading to assist emerging growth companies with their investor relations objectives.
• Institutional investors are increasingly looking for access to emerging growth companies for direct investments, as well as to better understand looming risks to the public companies they own
• Growth-oriented companies are staying private longer, but need access to capital from institutional-type sources
Jill VoonPrivate Company Access
City University of NY | Center for Advanced Technology
When it opens in the fall of 2014, the Advanced Science Research Center will bring CUNY to a landmark moment in its decade-long, multi-billion-dollar commitment to becoming a national leader in visionary scientific research of vital, real-world consequence.
A decade in the planning, the first phase of the ASRC is rapidly taking shape on the south end of the City College campus in Upper Manhattan: a striking glass-encased structure that will be at the center of CUNY’s expanding universe of science and embody a bold vision of 21st Century discovery.
The construction of a $350 million building with 200,000 square feet of world-class facilities would be big news for any institution, public or private. But sophistication and scale are only part of the ASRC story. At the center’s core will be an innovative approach to the scientific method itself, one that seeks to break down some of the walls between disparate but increasingly inter-related disciplines of applied science.
The ASRC will focus CUNY initiatives in five of the most energized areas of global research: Nanoscience. Photonics. Structural Biology. Neuroscience. Environmental Sciences.
Dr Myron WeckerDeputy Director
Your innovative solution
Carebag is a range of green friendly medical grade bags and liners equipped with a super absorbent pad, designed to replace or cover collection containers such as bedpan ; thus providing a safe solution for the collection, transport and disposal of body fluids whether infectious or not. Made with innovative polymers.
The excretas and body fluids management. Carebag has multiple benefits: improvement of hygiene and infection control ; decrease of infection rate ; reduction of Healthcare-Associated Infections (H.A.I.) such as the deadly and highly prevalent C diff. ; substantial cost savings generated by the Reduction of nursing and PPE savings.
Where collection containers such as bedpans or commode pails are used: Hospital (10 to 15% of hospitalization with the support of Infection Preventionnist, especially ICU, Emergency dpt, PACU, post op, cancer treatment center
Innovation: Inventor of the product / Leader / Continuous innovation / IP
CLEVEXEL Pharma invests its teams' know-how to catalyze innovative drug development projects and ensure their attractiveness on the market.
We are an integrated, one-stop-shop solution for the co-development of promising new therapeutic compounds. We partner with inventors to boost the development of their product from proof-of-concept in an animal model to proof-of-concept in human. The project is then outlicensed to a pharmaceutical company for Phase III and Market Access.